Dabrafenib | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Dabrafenib
Health Canada Patents

PharmaCompass Sponsored Ads

Contact Supplier

Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

Contact Supplier

pharmacompass-1-m-2025-08-25

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

pharmacompass-2-m-2025-08-25

Dabrafenib

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

19 API Suppliers, 1 USDMF, 1 EU WC, 3 NDC API, 16 Listed Suppliers, $ API Reference Price

19 API Suppliers
1 USDMF
1 EU WC
3 NDC API
16 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

85 Drugs in Development

85 Drugs in Development

INTERMEDIATES

22 Intermediate Suppliers

22 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

27 FDF Dossiers, 5 FDA Orange Book, 5 Europe, 15 Australia, 2 South Africa

27 FDF Dossiers
5 FDA Orange Book
5 Europe
15 Australia
2 South Africa

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 50MG BASE, CAPSULE;ORAL - EQ 75MG BASE

CAPSULE;ORAL - EQ 50MG BASE
CAPSULE;ORAL - EQ 75MG BASE

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 5 DKSH, 2 Gangwal Healthcare, 1 ACG Worldwide, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 10 Corel Pharma Chem, 2 DFE Pharma, 6 Gangwal Chemicals, 4 Ideal Cures, 10 Kerry, 1 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 8 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 1 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 9 Roquette, 6 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Sigachi Industries, 2 Silverline Chemicals, 2 The Dow Chemical Company, 2 Vasa Pharmachem

1 SPI Pharma
5 DKSH
2 Gangwal Healthcare
1 ACG Worldwide
4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
10 Corel Pharma Chem
2 DFE Pharma
6 Gangwal Chemicals
4 Ideal Cures
10 Kerry
1 Keval Exports
3 Kima Chemical
6 Lonza Capsugel
8 Microlex e.U
2 Nitika Pharmaceutical Specialities
1 Novo Excipients
1 Pharmatrans-Sanaq
1 Pluviaendo
2 Prachin Chemical
1 Qianhao Chemical (Hebei) Co., Ltd
1 Qualicaps
9 Roquette
6 Seppic
3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
8 Sigachi Industries
2 Silverline Chemicals
2 The Dow Chemical Company
2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

39 Coating Systems & Additives, 22 Fillers, Diluents & Binders, 14 Controlled & Modified Release, 12 Thickeners and Stabilizers, 10 Lubricants & Glidants, 9 Direct Compression, 7 Co-Processed Excipients, 7 Granulation, 6 Film Formers & Plasticizers, 5 Disintegrants & Superdisintegrants, 5 Empty Capsules, 4 Coloring Agents, 4 Rheology Modifiers, 4 Emulsifying Agents, 4 Chewable & Orodispersible Aids, 4 Vegetarian Capsules, 4 Taste Masking, 4 API Stability Enhancers, 1 Solubilizers

39 Coating Systems & Additives
22 Fillers, Diluents & Binders
14 Controlled & Modified Release
12 Thickeners and Stabilizers
10 Lubricants & Glidants
9 Direct Compression
7 Co-Processed Excipients
7 Granulation
6 Film Formers & Plasticizers
5 Disintegrants & Superdisintegrants
5 Empty Capsules
4 Coloring Agents
4 Rheology Modifiers
4 Emulsifying Agents
4 Chewable & Orodispersible Aids
4 Vegetarian Capsules
4 Taste Masking
4 API Stability Enhancers
1 Solubilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 44 News #PharmaBuzz

1 Data Compilation #PharmaFlow
44 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 5 Regulatory FDF Prices, 11 Annual Reports

1 US Medicaid Prescriptions
5 Regulatory FDF Prices
11 Annual Reports

MARKET PLACE

4 APIs, 1 FDF Dossiers

4 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

68 US Patents, 24 US Exclusivities, 9 Health Canada Patents

68 US Patents
24 US Exclusivities
9 Health Canada Patents

$ API Ref.Price (USD/KG) : 40,469 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

9 All

01 9Gowling WLG (Canada) LLP

filter Patent Reset all filters

9 All

01 32723396

02 32775803

03 32882437

filter Product Reset all filters

9 All

01 3DABRAFENIB MESYLATE

02 6Dabrafenib Mesylate

filter Dosage Reset all filters

9 All

01 6Capsule

02 3TABLET FOR SUSPENSION

filter Exp Date Reset all filters

9 All

01 32029-05-04

02 32030-10-15

03 32033-08-30

Dabrafenib Mesylate

Product Main Page

01

Gowling WLG (Canada) LLP

Dabrafenib Mesylate

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Canada

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-05-04

Date Granted : 2013-09-10

Dabrafenib Mesylate

Brand Name : TAFINLAR

Patent Number : 2723396

Filing Date : 2009-05-04

Strength per Unit : 50 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2029-05-04

Date Granted : 2013-09-10

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Gowling WLG (Canada) LLP

Dabrafenib Mesylate

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Canada

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-05-04

Date Granted : 2013-09-10

Dabrafenib Mesylate

Brand Name : TAFINLAR

Patent Number : 2723396

Filing Date : 2009-05-04

Strength per Unit : 75 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2029-05-04

Date Granted : 2013-09-10

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Gowling WLG (Canada) LLP

Dabrafenib Mesylate

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-10-15

Date Granted : 2017-11-21

Dabrafenib Mesylate

Brand Name : TAFINLAR

Patent Number : 2775803

Filing Date : 2010-10-15

Strength per Unit : 50 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2030-10-15

Date Granted : 2017-11-21

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Gowling WLG (Canada) LLP

Dabrafenib Mesylate

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-08-30

Date Granted : 2021-03-02

Dabrafenib Mesylate

Brand Name : TAFINLAR

Patent Number : 2882437

Filing Date : 2013-08-30

Strength per Unit : 50 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2033-08-30

Date Granted : 2021-03-02

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Gowling WLG (Canada) LLP

Dabrafenib Mesylate

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-10-15

Date Granted : 2017-11-21

Dabrafenib Mesylate

Brand Name : TAFINLAR

Patent Number : 2775803

Filing Date : 2010-10-15

Strength per Unit : 75 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2030-10-15

Date Granted : 2017-11-21

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Gowling WLG (Canada) LLP

Dabrafenib Mesylate

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-08-30

Date Granted : 2021-03-02

Dabrafenib Mesylate

Brand Name : TAFINLAR

Patent Number : 2882437

Filing Date : 2013-08-30

Strength per Unit : 75 mg

Dosage Form : Capsule

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2033-08-30

Date Granted : 2021-03-02

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

07

Gowling WLG (Canada) LLP

Dabrafenib Mesylate

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-05-04

Date Granted : 2013-09-10

Dabrafenib Mesylate

Brand Name : TAFINLAR

Patent Number : 2723396

Filing Date : 2009-05-04

Strength per Unit : 10mg

Dosage Form : TABLET FOR SUSPENSION

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2029-05-04

Date Granted : 2013-09-10

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

08

Gowling WLG (Canada) LLP

Dabrafenib Mesylate

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-10-15

Date Granted : 2017-11-21

Dabrafenib Mesylate

Brand Name : TAFINLAR

Patent Number : 2775803

Filing Date : 2010-10-15

Strength per Unit : 10mg

Dosage Form : TABLET FOR SUSPENSION

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2030-10-15

Date Granted : 2017-11-21

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

09

Gowling WLG (Canada) LLP

Dabrafenib Mesylate

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-08-30

Date Granted : 2021-03-02

Dabrafenib Mesylate

Brand Name : TAFINLAR

Patent Number : 2882437

Filing Date : 2013-08-30

Strength per Unit : 10mg

Dosage Form : TABLET FOR SUSPENSION

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2033-08-30

Date Granted : 2021-03-02

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!